Treatment of Patients With Major Depressive Disorder With MK0869 (0869-059)

Summary

A clinical study to determine the efficacy and safety of MK0869 in the treatment of depression

Timeline

Start

2001-09-20

Primary completion

2003-12-22

Completion

2004-03-24

Outcome

Missed primary endpoint

paper No statistically significant differences from placebo on the HAM-D(17) were observed at week 8 for either dose of aprepitant in any of the trials PMID 16248986 ↗

Publications

• Background Liu KS, Snavely DB, Ball WA, Lines CR, Reines SA, Potter WZ. Is bigger better for depression trials? J Psychiatr Res. 2008 Jul;42(8):622-30. doi: 10.1016/j.jpsychires.2007.07.003. Epub 2007 Sep 7.
• Results Keller M, Montgomery S, Ball W, Morrison M, Snavely D, Liu G, Hargreaves R, Hietala J, Lines C, Beebe K, Reines S. Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol Psychiatry. 2006 Feb 1;59(3):216-23. doi: 10.1016/j.biopsych.2005.07.013. Epub 2005 Oct 24.

Drugs

Indications